Opendata, web and dolomites

OligoGpivotalCF SIGNED

A pivotal phase IIb clinical trial of inhaled alginate oligosaccharide (OligoG) for cystic fibrosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "OligoGpivotalCF" data sheet

The following table provides information about the project.

Coordinator
ALGIPHARMA AS 

Organization address
address: INDUSTRIVEIEN 33
city: SANDVIKA
postcode: 1337
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Project website https://oligogpivotalcf.eu/
 Total cost 12˙163˙748 €
 EC max contribution 6˙013˙748 € (49%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALGIPHARMA AS NO (SANDVIKA) coordinator 3˙224˙712.00
2    SMERUD MEDICAL RESEARCH INTERNATIONAL AS NO (OSLO) participant 2˙501˙250.00
3    KLINIKUM DER UNIVERSITAET ZU KOELN DE (KOELN) participant 123˙037.00
4    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 79˙990.00
5    EUROPEAN CYSTIC FIBROSIS SOCIETY DK (KARUP) participant 52˙258.00
6    CYSTIC FIBROSIS EUROPE EV DE (BONN) participant 32˙500.00

Map

 Project objective

The objective of the current proposal is to advance the orphan drug OligoG CF-5/20 (OligoG) through a pivotal phase IIb clinical trial, to enable a new and improved therapeutic approach for the orphan disease cystic fibrosis by 2020.

The study drug is an alginate oligosaccharide derived from seaweed. Several properties relevant to the treatment of CF have been demonstrated using in vitro and ex vivo model systems including release of stagnant mucus, disruption of bacterial biofilm and increased bacterial susceptibility to antibiotics. OligoG received an EU Orphan Drug Medicinal Product Designation in 2007 and an FDA Orphan Drug Designation February 2016, for the treatment of cystic fibrosis.

The planned clinical trial will include 120 CF patients from approx. 35 European sites in coordination with the European Clinical Trial Network. The final study design, selection criteria, procedures and endpoints will be based on results from a recently finalized phase II study and will follow scientific advice and protocol assistance sought at the European Medicines Agency (EMA). A set of clinical and exploratory endpoints will be defined to assess the various effects of OligoG, comprising lung function assessed by spirometry and Lung Clearance Index (LCI) measurements, infection status assessed by frequency of pulmonary exacerbations and non-culture-dependent microbiology, and patient reported outcomes assessed by questionnaires, including standardised CF questionnaires (CFQ-R).

A successful trial will enable preparation of international applications for conditional marketing authorisation (cMAA) throughout Europe and a New Drug Application (NDA) in the US, for the treatment of cystic fibrosis lung disease. In accordance with the work programme, a successful project will thus imply a new and improved therapeutic approach within cystic fibrosis available for CF patients by 2020.

 Deliverables

List of deliverables.
Data Management Plan Open Research Data Pilot 2019-07-23 17:23:33
Web-site launch - project communication Websites, patent fillings, videos etc. 2019-05-31 16:32:41

Take a look to the deliverables list in detail:  detailed list of OligoGpivotalCF deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OLIGOGPIVOTALCF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OLIGOGPIVOTALCF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More